Real-World Outcomes of First-Line Treatment With Anti–PD(L)1-Based Combination Therapy for Nonsquamous Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in Europe, Japan, and the United States
This study assessed the real-world clinical effectiveness of 1L anti-PD(L)1-based combination therapy for mnsqNSCLC. Results from this study were generally consistent with previous clinical trials and published real-world evidence in 1L mnsqNSCLC.
Authors
- Ticiana A.B. Leal (ORCID: https://orcid.org/0000-0002-3735-9063)
- Carmine Rossi (ORCID: https://orcid.org/0000-0001-5801-6927)
- Stephen V. Liu (ORCID: https://orcid.org/0000-0002-4852-3914)
- Anandaroop Dasgupta
- Pragya Rai (ORCID: https://orcid.org/0000-0002-7428-7273)
- Dominick Latrémouille-Viau (ORCID: https://orcid.org/0000-0002-8565-9220)
- Fabrice Barlési (ORCID: https://orcid.org/0000-0001-5793-3539)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Emory University (US)
- Georgetown University (US)
- Université Paris-Saclay (FR)
- Georgetown University Medical Center (US)
- Institut Gustave Roussy (FR)
- Eisai (United States) (US)
Publication Details
- Journal
- JCO Global Oncology
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1200/go.24.00138
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.84